Anaplastic oligodendroglioma

Summary

Anaplastic oligodendroglioma (MONDO:0016696) is a disease and 60 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, carmustine, and dabrafenib. A subtype of oligodendroglial tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 60

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.09	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.11	United States	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	anaplastic oligodendroglioma
Mondo ID	MONDO:0016696
EFO	EFO:0002501
Orphanet	251630
DOID	DOID:7154
NCIT	C4326
UMLS	C0334590
MedGen	90812
GARD	0009472
MedDRA	10026659
Is cancer (heuristic)	no

Also known as: anaplastic oligodendroglioma · malignant oligodendroglioma · oligodendroglioma, anaplastic, malignant · oligodendroglioma, malignant · undifferentiated oligodendroglioma · WHO grade III oligodendroglial neoplasm · WHO grade III oligodendroglial tumor · WHO grade III oligodendroglial tumour

Data availability: 10 cell lines.

Disease family

This is a subtype of oligodendroglial tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › malignant glioma › oligodendroglial tumor › anaplastic oligodendroglioma

Related subtypes (1): oligodendroglioma

Subtypes (1): IDH-mutant and 1p/19q-codeleted oligodendroglioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carmustine	Phase 3 (in late-stage trials)
Temozolomide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aflibercept, Bevacizumab, Carboplatin, Cilengitide, Etirinotecan Pegol, Etoposide, Nintedanib, Streptozocin, Vandetanib.

Clinical trials & evidence

Clinical trials

Clinical trials: 60.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	31
PHASE2	13
Not specified	9
PHASE1/PHASE2	4
PHASE4	1
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03975829	PHASE4	RECRUITING	Pediatric Long-Term Follow-up and Rollover Study
NCT01656980	PHASE3	UNKNOWN	Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
NCT03180502	PHASE2	ACTIVE_NOT_RECRUITING	Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NCT04623931	PHASE2	RECRUITING	Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
NCT07468136	PHASE1/PHASE2	NOT_YET_RECRUITING	Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
NCT00004688	PHASE2	COMPLETED	Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
NCT00062504	PHASE2	TERMINATED	Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
NCT00243490	PHASE2	WITHDRAWN	Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors
NCT00303849	PHASE1/PHASE2	COMPLETED	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
NCT00362570	PHASE2	COMPLETED	Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
NCT00667394	PHASE2	COMPLETED	Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
NCT00995007	PHASE2	COMPLETED	A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
NCT01095094	PHASE2	TERMINATED	Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
NCT01380782	PHASE2	COMPLETED	BIBF 1120 for Recurrent High-Grade Gliomas
NCT01663012	PHASE2	COMPLETED	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
NCT01721577	PHASE1/PHASE2	TERMINATED	Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
NCT01847235	PHASE2	COMPLETED	Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
NCT02684058	PHASE2	COMPLETED	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
NCT05737212	PHASE1/PHASE2	TERMINATED	Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
NCT02192359	PHASE1	ACTIVE_NOT_RECRUITING	Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
NCT04541082	PHASE1	RECRUITING	Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04978727	PHASE1	ACTIVE_NOT_RECRUITING	A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
NCT05698524	PHASE1	RECRUITING	A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
NCT00064779	PHASE1	COMPLETED	Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
NCT00390299	PHASE1	COMPLETED	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00734682	PHASE1	COMPLETED	A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
NCT00734864	PHASE1	WITHDRAWN	Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
NCT00884416	PHASE1	COMPLETED	Sorafenib in Newly Diagnosed High Grade Glioma
NCT01082926	PHASE1	COMPLETED	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
NCT01144247	PHASE1	COMPLETED	Cellular Immunotherapy Study for Brain Cancer
NCT01156584	PHASE1	COMPLETED	A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
NCT01250470	PHASE1	COMPLETED	Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
NCT01316809	PHASE1	COMPLETED	AZD8055 for Adults With Recurrent Gliomas
NCT01339039	PHASE1	TERMINATED	Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
NCT01392209	PHASE1	COMPLETED	Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
NCT01470794	PHASE1	COMPLETED	Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
NCT01522820	PHASE1	COMPLETED	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01975116	PHASE1	COMPLETED	p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
NCT01985256	PHASE1	COMPLETED	Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
NCT02101905	PHASE1	COMPLETED	Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MERCAPTOPURINE ANHYDROUS	4	3
CARMUSTINE	4	2
DABRAFENIB	4	2
PLERIXAFOR	4	2
REGADENOSON ANHYDROUS	4	2
TRAMETINIB	4	2
AMINOLEVULINIC ACID	4	1
EFLORNITHINE	4	1
ETOPOSIDE PHOSPHATE	4	1
FILGRASTIM	4	1
MANNITOL	4	1
MEBENDAZOLE	4	1
NINTEDANIB	4	1
RETIFANLIMAB	4	1
SODIUM THIOSULFATE	4	1
SONIDEGIB	4	1
SORBITOL	4	1
STREPTOZOCIN	4	1
VANDETANIB	4	1
ABEXINOSTAT	3	1
ANG1005	3	1
CINTREDEKIN BESUDOTOX	3	1
ETIRINOTECAN PEGOL	3	1
PERIFOSINE	3	1
AXL-1717	2	1
EFLORNITHINE, (S)-	2	1
TALAMPANEL	2	1
TANDUTINIB	2	1
VOCIMAGENE AMIRETROREPVEC	2	1
AZD-8055	1	1